Has Meera Mohan, MD received payments from drug or device companies?

Yes. Drug and device makers reported $48,834 in general payments to Meera Mohan, MD across 37 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Meera Mohan, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Meera Mohan, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Meera Mohan, MD

Hematology & Oncology · Milwaukee, WINPI 1962718130

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (56.3%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 10 manufacturers reported payments, led by Sanofi at 53.4% of the total. Reporting peaked in 2024 at $27,391 and has fallen 93.7% since, to $1,728 in 2025. Among hematology & oncology clinicians in WI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$48,834in general payments, 2019–2025

Across 37 payments — averaging $1319.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Sanofi$26K
Pfizer$13K
Janssen Scientific Affairs, LLC$3K
Legend Biotech USA Inc.$2K
E.r. Squibb & Sons, L.L.C.$2K
Adaptive Biotechnologies Corporation$2K
plus $636 from 4 others

$5,525,974in research payments, 2019–2025

Across 96 payments — averaging $57,562 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Sanofi$4.6M
Takeda Pharmaceuticals U.S.A., Inc.$414K
Bristol Myers Squibb$202K
GSK$88K
Amgen$83K
Epizyme, Inc.$69K
plus $75K from 4 others

What the payments were for

Consulting fees$27,51356%
Speaking & faculty fees$12,82826%
Travel & lodging$7,22015%
Food & beverage$1,2032%
Education$700%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Sanofi	15	$26,099
Pfizer	9	$12,804
Janssen Scientific Affairs, LLC	3	$2,791
Legend Biotech USA Inc.	1	$2,463
E.r. Squibb & Sons, L.L.C.	1	$2,422
Adaptive Biotechnologies Corporation	2	$1,620
AstraZeneca	2	$222
Takeda Pharmaceuticals U.S.A., Inc.	2	$216
Genentech, Inc.	1	$128
Astellas Pharma US Inc	1	$70

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

SARCLISA$22,288
ELREXFIO$7,502
ELITEK$3,625
CARVYKTI$2,463
TECVAYLI$1,908
clonoSEQ$1,600
DARZALEX$840
NINLARO$216

How this compares

$48,834 in reported general payments places this provider in the 90th percentile of 248 hematology & oncology providers in Wisconsin.

See all hematology & oncology providers in Wisconsin →

Medicare billing

Part B allowed, 2024

$52,238

Medicare patients

131

Services billed

565

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
VenclextaVenetoclax	18	$192,152
Acyclovir	209	$3,926
BexseroMeningococcal B Vaccine,4-Comp	14	$3,193
Menveo A-C-Y-W-135-DipMening Vac A,c,y,w-135 Dip/Pf	14	$2,666
Fluconazole	24	$1,272
CholestyramineCholestyramine (With Sugar)	13	$1,111
Ondansetron Hcl	23	$545
Allopurinol	20	$233
Dexamethasone	19	$216
Prochlorperazine Maleate	13	$202
Levofloxacin	21	$167
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim	31	$156
Levetiracetam	11	$120
Potassium Chloride	18	$87

Paid to pharmacies, not to this prescriber.

Other hematology & oncology in Milwaukee

Parameswaran HariMilwaukee$1.3M
Sayed Mehdi HamadaniMilwaukee$546K
Binod DhakalMilwaukee$535K
Deepak KilariMilwaukee$359K
Ehab AtallahMilwaukee$344K
Nirav ShahMilwaukee$207K
Razelle KurzrockMilwaukee$199K
Syed AbutalibMilwaukee$154K
Patrick FoyMilwaukee$132K
Guru Subramanian Guru MurthyMilwaukee$113K

See the full list for Wisconsin →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →